Abbott Labs (ABT)

A European regulatory body plans to examine whether certain cholesterol drugs have long-term clinical benefits and one potential outcome could be their withdrawal from the market if they come up short.
The review will have implications for Abbott Laboratories and the pharmaceutical unit of Solvay SA, which Abbott is in the process of acquiring for $6.6 billion. Abbott and Solvay co-market the drugs TriCor and Trilipix, which are in a category the European regulatory body will assess.

Oct 27 · 11:16:00 AM · Source: Easy Bourse
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto